Zevra Therapeutics (NASDAQ:ZVRA) Given Buy Rating at HC Wainwright

Posted by Francis Steltz on Jun 23rd, 2026

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report)‘s stock had its “buy” rating reissued by HC Wainwright in a report released on Tuesday,Benzinga reports. They currently have a $26.00 price target on the stock. HC Wainwright’s price objective points to a potential upside of 101.49% from the stock’s current price.

Several other equities analysts have also recently commented on ZVRA. BTIG Research reaffirmed a “buy” rating and issued a $27.00 price target (up from $23.00) on shares of Zevra Therapeutics in a report on Tuesday, June 9th. Canaccord Genuity Group lifted their price objective on Zevra Therapeutics from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Tuesday, June 9th. Guggenheim boosted their price objective on Zevra Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a research report on Wednesday, June 10th. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research note on Tuesday, June 9th. Finally, Citizens Jmp boosted their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “market outperform” rating in a report on Tuesday, June 9th. Eight equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $29.29.

Check Out Our Latest Research Report on ZVRA

Zevra Therapeutics Stock Up 2.0%

Zevra Therapeutics stock traded up $0.25 during mid-day trading on Tuesday, reaching $12.90. The company had a trading volume of 376,757 shares, compared to its average volume of 1,307,513. The firm has a market cap of $762.88 million, a price-to-earnings ratio of 6.47 and a beta of 0.91. The company has a 50 day moving average of $11.07 and a 200-day moving average of $9.69. Zevra Therapeutics has a 52 week low of $7.16 and a 52 week high of $14.27.

Zevra Therapeutics (NASDAQ:ZVRA – Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.12. The company had revenue of $36.22 million for the quarter, compared to the consensus estimate of $31.96 million. Zevra Therapeutics had a net margin of 101.58% and a return on equity of 51.49%. On average, analysts predict that Zevra Therapeutics will post 0.56 earnings per share for the current fiscal year.

Institutional Trading of Zevra Therapeutics

A number of large investors have recently bought and sold shares of the stock. Stratos Wealth Partners LTD. grew its holdings in Zevra Therapeutics by 78.6% during the 4th quarter. Stratos Wealth Partners LTD. now owns 409,000 shares of the company’s stock worth $3,665,000 after acquiring an additional 180,000 shares during the last quarter. JPMorgan Chase & Co. raised its position in shares of Zevra Therapeutics by 1,458.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 438,984 shares of the company’s stock valued at $4,175,000 after acquiring an additional 410,823 shares during the period. Royce & Associates LP bought a new position in shares of Zevra Therapeutics during the third quarter worth $6,574,000. Hennion & Walsh Asset Management Inc. bought a new position in Zevra Therapeutics during the fourth quarter worth about $1,251,000. Finally, Kingdon Capital Management L.L.C. grew its position in shares of Zevra Therapeutics by 44.4% in the 3rd quarter. Kingdon Capital Management L.L.C. now owns 650,000 shares of the company’s stock valued at $6,182,000 after purchasing an additional 200,000 shares during the period. 35.03% of the stock is currently owned by institutional investors.

About Zevra Therapeutics

(Get Free Report)

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.